Table 2. . Recruiting clinical trials with tyrosine kinase inhibitors in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
| Study | Age (years)/status | Treatment | Identifier |
|---|---|---|---|
| Phase II NCI | ≥65/newly diagnosed | Dasatinib + blinatumomab + prednisone | NCT02143414 |
| Phase II MDACC | ≥10/Ph-like ALL | Dasatinib + chemo (hyper-CVAD) | NCT02420717 |
| Phase I MSKCC | ≥40/newly diagnosed | Dasatinib + ruxolitinib + Dex | NCT02494882 |
| Phase II University of California, San Diego | 18–60/newly diagnosed | Dasatinib + rituximab† + chemo | NCT02043587 |
| Phase I Novartis Pharmaceuticals | ≥18/R/R to TKIs | ABL001 + dasatinib or imatinib or nilotinib | NCT02081378 |
| Phase III PETHEMA | ≥55/newly diagnosed | Dasatinib or imatinib + chemo | NCT01376427 |
| Phase II MDACC | ≥55/newly diagnosed | Dasatinib or imatinib + rituximab† + chemo (hyper-CVAD) | NCT01319981 |
| Phase I and II University of Toronto | ≥18/R/R to TKIs | Nilotinib + ruxolitinib | NCT01914484 |
| Phase III GRAALL (GRAAPH 2014) | 18–59/newly diagnosed | Nilotinib + chemo | NCT02611492 |
| Phase II OHSU Knight Cancer Institute | 21–70/relapsed | Nilotinib or ponatinib or dasatinib | NCT01620216 |
| Phase I and II Novartis Pharmaceuticals | ≥18/R/R | Nilotinib + ruxolitinib | NCT02253277 |
| Phase II MDACC | ≥18/R/R | Bosutinib + inotuzumab ozogamicin | NCT02311998 |
| Phase II GIMEMA | ≥18/newly diagnosed | Ponatinib | NCT01641107 |
| Phase II MDACC | ≥18/newly diagnosed | Ponatinib + chemo (hyper-CVAD) | NCT01424982 |
| Phase IV PETHEMA | <55/newly diagnosed | Imatinib + chemo | NCT01491763 |
| Phase II Asan Medical Center (RADICAL) | ≥15/newly diagnosed | Imatinib + rituximab† + chemo | NCT01429610 |
†In patients expressing CD20.
ABL001: A potent allosteric BCR–ABL inhibitor; Chemo: Chemotherapy; Dex: Dexamethasone; GIMEMA: Gruppo Italiano Malattie Ematologiche dell'Adulto; GRAALL: Group for Research in Adult Acute Lymphoblastic Leukemia; GRAAPH: Group for Research in Adult Philadelphia chromosome-positive Acute Lymphoblastic Leukemia; Hyper-CVAD: Fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with cycles of high-dose methotrexate and cytarabine; MDACC: MD Anderson Cancer Center; MSKCC: Memorial Sloan Kettering Cancer Center; NCI: National Cancer Institute; PETHEMA: Programa para el Tratamiento de Hemopatias Malignas; Ph+ ALL: Philadelphia chromosome-positive acute lymphoblastic leukemia; R/R: Relapsed/refractory; TKI: Tyrosine kinase inhibitor.